MedTrace Logo

Progesterone for the Treatment of COVID-19 in Hospitalized Men

NCT04365127 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2021-01-27

No results posted yet for this study

Summary

The purpose of this study is to assess safety and efficacy of progesterone for treatment of COVID-19 in hospitalized men.

Conditions

Interventions

DRUG

Progesterone 100 MG

Subcutaneous administration twice daily

Sponsors & Collaborators

  • IBSA Institut Biochimique SA

    collaborator INDUSTRY

  • Sara Ghandehari

    lead OTHER

Principal Investigators

  • Sara Ghandehari, MD · Cedars-Sinai Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-27
Primary Completion
2020-08-20
Completion
2020-08-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04365127 on ClinicalTrials.gov